PMID: 8938270Dec 1, 1995Paper

Definition of tumor antigens suitable for vaccine construction

Seminars in Cancer Biology
J J Lewis, A N Houghton

Abstract

The treatment of cancer with tumor vaccines has been a goal of physicians and scientists ever since effective immunization against infectious disease with vaccines was developed. In the past, major tumor antigens had not been molecularly characterized. Recent advances are, however, beginning to define potential molecular targets and strategies and this had evolved with the principle that T-cell mediated responses are a key target for approaches to cancer immunization. In addition, these antigens are not truly foreign and tumour antigens fit more with a self/altered self paradigm, compared to a non-self paradigm for antigens recognized in infectious diseases. Potential antigens include the glycolipids and glycoproteins (e.g. gangliosides), the developmental antigens (e.g. MAGE, tyrosinase, melan-A and gp75) and mutant oncogene products (e.g. p53, ras, and HER-2/neu). Innovations for construction of cancer vaccines are emerging from these advances in molecular immunology and cancer biology. While vaccines against infectious agents are models for vaccine development, there are clearly distinct considerations and problems associated with cancer vaccines. One of the focal issues in designing active cancer immunotherapy is that cance...Continue Reading

References

Jul 15, 1979·International Journal of Cancer. Journal International Du Cancer·P O LivingstonL J Old
Apr 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·A M DavidoffJ R Marks
Jun 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H HerbstH Stein
Jan 1, 1991·The Journal of Experimental Medicine·S Jung, H J Schluesener
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D L BarndO J Finn
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·P O LivingstonM J Calves
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·D M EuhusD L Morton
May 1, 1988·The Journal of General Virology·L S YoungA B Rickinson
May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R J CoteL J Old
Mar 15, 1987·International Journal of Cancer. Journal International Du Cancer·M HérinT Boon
Oct 1, 1974·Annals of Surgery·D L MortonF C Sparks
Feb 29, 1968·The New England Journal of Medicine·R E WilsonJ E Murray
Dec 15, 1983·International Journal of Cancer. Journal International Du Cancer·M J MattesK O Lloyd
Oct 15, 1982·International Journal of Cancer. Journal International Du Cancer·L V CrawfordR D Bulbrook
Jun 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M DürstH zur Hausen
Sep 17, 1983·British Medical Journal·D J McCanceA Singer
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·A KnuthL J Old
Mar 1, 1993·Scientific American·T Boon
May 6, 1965·Zeitschrift für Zellforschung und mikroskopische Anatomie·R S SNELL

❮ Previous
Next ❯

Citations

Feb 13, 2001·Journal of Biotechnology·F X BerthetC Vinals
Jul 14, 2000·Journal of Hematotherapy & Stem Cell Research·J Barrett, R Childs
Apr 18, 2000·Annals of Surgery·J J LewisM F Brennan
Aug 7, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jonathan J Lewis
Aug 17, 1999·Cancer Treatment Reviews·A M Gillespie, R E Coleman
Nov 12, 2016·Cancer Gene Therapy·W F MoranoW B Bowne
Aug 29, 2018·International Journal of Molecular Sciences·Virgil E J C SchijnsApostolos Stathopoulos
Nov 26, 1999·Advances in Surgery·J J Lewis, M F Brennan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.